NUVO RESEARCH TO PRESENT AT BIOFINANCE 2011
May 25, 2011
MISSISSAUGA, ON, May 25, 2011 /CNW/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that Dan Chicoine, the Company's Chairman and Co-Chief Executive Officer, will present at BioFinance 2011 on Wednesday, June 1, at 11:00 a.m. Eastern Time. The conference will be held at the St. Andrew's Club & Conference Centre in Toronto, Ontario.
Mr. Chicoine will provide a corporate update, including information about the Company's portfolio of topical pain products and the recently closed ZARS acquisition.
In addition, Mr. Chicoine will participate in a BioFinance panel presentation titled, 'Strategic Alliances - The Pharma Perspective', the same day at 9:00 a.m. Eastern Time.
Neither event is being webcast.
BioFinance is a prominent Canadian investor conference for the life sciences industry. The two-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies span a range of industries including biologics, medical devices, drug delivery, vaccines, and diagnostics.
About Nuvo Research Inc.
Nuvo Research is a publicly traded, Canadian pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition. The Company's Pain Group, located in West Chester, Pennsylvania, is focused on the development and commercialization of topically delivered pain products. The Company's product portfolio includes Pennsaid, Pliaglis, and Synera. Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID), is used to treat the signs and symptoms of osteoarthritis of the knee. Pennsaid is sold in the United States by Mallinckrodt Inc., a Covidien company (NYSE: COV), in Canada by Paladin Labs Inc. (TSX:PLB) and in several European countries. Pliaglis is a topical local anesthetic cream, which is U.S. Food and Drug Administration (FDA) approved to provide topical local analgesia for superficial dermatological procedures. ZARS has licensed worldwide marketing rights to Pliaglis to GaldermaPharma S.A., a global specialty pharmaceutical company focused on dermatology. Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial and in Europe, for surface anaesthesia of normal intact skin. ZARS currently markets Synera in the U.S. and its licensing partner, EuroCept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan) in several European countries. Through its subsidiary, Nuvo Research AG, based in Leipzig, Germany, the Company is also developing the compound WF10, for the treatment of immune related diseases. For more information, please visit www.nuvoresearch.com.
For further information:
about Nuvo, please contact:
Westwicke Partners LLC
Tel: (443) 213-0506